Aged garlic extract improves homocysteine-induced endothelial dysfunction in macro- and microcirculation

Journal of Nutrition

Volumn 136, Issue 3, 2006, Pages

  Weiss, Norbert ^a   Ide, Nagatoshi ^a   Abahji, Thomas ^a   Nill, Lars ^a   Keller, Christiane ^a   Hoffmann, Ulrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Aged garlic extract; Endothelial function; Hyperhomocysteinemia; Nitric oxide; Oxidant stress

Indexed keywords

ACETYLCHOLINE; GARLIC EXTRACT; HOMOCYSTEINE; METHIONINE; NITRIC OXIDE; S ALLYLCYSTEINE;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; BIOAVAILABILITY; BRACHIAL ARTERY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERPOLARIZATION; LASER DOPPLER FLOWMETRY; MICROCIRCULATION; NONHUMAN; OXIDATION REDUCTION REACTION; PERFUSION; ULTRASOUND; VASCULAR DISEASE; VASODILATATION;

ALLIUM SATIVUM; ANIMALIA;

EID: 33644836981     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/136.3.750s     Document Type: Conference Paper

References (69)

1. Bautista LE, Arenas IA, Penuela A, Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol. 2002;55:882-7.
2. Darius H, Pittrow D, Haberl R, Trampisch HJ, Schuster A, Lange S, Tepohl HG, Allenberg JR, Diehm C. Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross-sectional study of 6880 primary care patients. Eur J Clin Invest. 2003;33:751-7.
3. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemostas. 2005;3:292-9.
4. Weiss N, Hilge R, Hoffmann U. Mild hyperhomocysteinemia: risk factor or just risk predictor for cardiovascular diseases? Vasa. 2004;33:191-203.
5. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med. 2002;7:227-39.
6. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation. 2000;102:871-5.
7. Kritharides L, Stocker R. The use of antioxidant supplements in coronary heart disease. Atherosclerosis. 2002;164:211-9.
8. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293:1338-47.
9. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213-8.
10. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107:992-5.
11. Weiss N, Heydrick SJ, Postea O, Keller C, Keaney JFJ, Loscalzo J. Influence of hyperhomocysteinemia on the cellular redox state - impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med. 2003;41:1455-61.
12. Worthley SG, Osende JI, Helft G, Badimon JJ, Fuster V. Coronary artery disease: pathogenesis and acute coronary syndromes. Mt Sinai J Med. 2001;68:167-81.
13. Forgione MA, Leopold JA, Loscalzo J. Roles of endothelial dysfunction in coronary artery disease. Curr Opin Cardiol. 2000;15:409-15.
14. Guerra R, Jr., Brotherton AF, Goodwin PJ, Clark CR, Armstrong ML, Harrison DG. Mechanisms of abnormal endothelium-dependent vascular relaxation in atherosclerosis: implications for altered autocrine and paracrine functions of EDRF. Blood Vessels. 1989;26:300-14.
15. Luscher TF, Richard V, Tschudi M, Yang ZH, Boulanger C. Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol. 1990;15:519-27.
16. Cooke JP, Stamler J, Andon N, Davies PF, McKinley G, Loscalzo J. Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J Physiol. 1990;259:H804-12.
17. Ignarro LJ, Harbison RG, Wood KS, Kadowitz PJ. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther. 1986;237:893-900.
18. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide. 2001;5:88-97.
19. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997;96:2542-4.
20. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium- dependent vasodilation in humans. Circulation. 1997;95:1119-21.
21. Holven KB, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, Gullestad L, Hagve TA, Svilaas A, et al. Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects. Am J Med. 2001;110:536-42.
22. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Bones C, Newcombe RG, Lewis MJ. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation. 1998;98:1848-52.
23. Hanratty CG, McAuley DF, McGurk C, Young IS, Johnston GD. Homocysteine and endothelial vascular function. Lancet. 1998;351:1288-9.
24. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 1999;99:1156-60.
25. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999;100:1161-8.
26. Lambert J, van den Berg M, Steyn M, Rauwerda JA, Donker AJ, Stehouwer CD. Familial hyperhomocysteinaemia and endothelium-dependent vasodilatation and arterial distensibility of large arteries. Cardiovasc Res. 1999;42:743-51.
27. Chao CL, Kuo TL, Lee YT. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation. 2000;101:485-90.
28. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab. 2005;6:27-36.
29. Wilcken DE, Wang XL, Adachi T, Hara H, Duarte N, Green K, Wilcken B. Relationship between homocysteine and superoxide dismutase in homocystinuria: possible relevance to cardiovascular risk. Arterioscler Thromb Vasc Biol. 2000;20:1199-202.
30. Yamamoto M, Hara H, Adachi T. Effects of homocysteine on the binding of extracellular-superoxide dismutase to the endothelial cell surface. FEBS Lett. 2000;486:159-62.
31. Upchurch GR, Jr., Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997;272:17012-7.
32. Weiss N, Zhang Y, Loscalzo J. Homocyst(e)ine impairs cellular glutathione peroxidase expression and promotes endothelial dysfunction in an animal model of hyperhomocyst(e)inemia. Circulation. 2000;102:II-238.
33. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, Loscalzo J. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arterioscler Thromb Vasc Biol. 2002;22:34-41.
34. Raghuveer G, Sinkey CA, Chenard C, Stumbo P, Haynes WG. Effect of vitamin E on resistance vessel endothelial dysfunction induced by methionine. Am J Cardiol. 2001;88:285-90.
35. Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, Farzati B, Giugliano D. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA. 1999;281:2113-8.
36. Postea O, Krotz F, Henger A, Keller C, Weiss N. Stereospecific and redox sensitive increase in monocyste adhesion to endothelial by homycysteine. Arterioscler Thromb Vasc Biol. Published online Dec 22, 2001. Available from: http://atvb.ahajournals.org, DOI: 10.1161/01.ATV.0000201039.21705.dc.
37. Forgione MA, Weiss N, Heydrick S, Cap A, Klings ES, Bierl C, Eberhardt RT, Farber HW, Loscalzo J. Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2002;282:H1255-61.
38. Postea O, Krotz F, Henger A, Keller C, Weiss N. Stereospecific and redox sensitive increase in monocyste adhesion to endothelial cells by homocysteine. Arterioscler Thromb Vasc Biol. Published online Dec 22, 2005. Available from: http://atvb.ahajournals.org, DOI: 10.1161/01.ATV.0000201039.21705.dc.
39. Vita JA, Frei B, Holbrook M, Gokce N, Leaf C, Keaney JF Jr. L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease. J Clin Invest. 1998;101:1408-14.
40. Amagase H, Petesch BL, Matsuura H, Kasuga S, Itakura Y. Intake of garlic and its bioactive components. J Nutr. 2001;131:955S-62S.
41. Imai J, Ide N, Nagae S, Moriguchi T, Matsuura H, Itakura Y. Antioxidant and radical scavenging effects of aged garlic extract and its constituents. Planta Med. 1994;60:417-20.
42. Ide N, Lau BH. S-Allylcysteine attenuates oxidative stress in endothelial cells. Drug Dev Ind Pharm. 1999;25:619-24.
43. Dillon SA, Lowe GM, Billington D, Rahman K. Dietary supplementation with aged garlic extract reduces plasma and urine concentrations of 8-isoprostaglandin F(2 alpha) in smoking and nonsmoking men and women. J Nutr. 2002;132:168-71.
44. Gengz Z, Lau BHS. Aged garlic extract modulates glutathione redox cycle and superoxide dismutase activity in vascular endothelial cells. Phytother Res. 1997;11:54-6.
45. Wei Z, Lau BHS. Garlic inhibits free radical generation and augments antioxidant enzyme activity in vascular endothelial cells. Nutr Res. 1998;18:61-70.
46. Ide N, Nelson AB, Lau BH. Aged garlic extract and its constituents inhibit Cu(21)-induced oxidative modification of low density lipoprotein. Planta Med. 1997;63:263-4.
47. Lau BH. Suppression of LDL oxidation by garlic. J Nutr. 2001;131:985S-8S.
48. Ide N, Lau BH. Garlic compounds minimize intracellular oxidative stress and inhibit nuclear factor-kappa b activation. J Nutr. 2001;131:1020S-6S.
49. Morihara N, Sumioka I, Moriguchi T, Uda N, Kyo E. Aged garlic extract enhances production of nitric oxide. Life Sci. 2002;71:509-17.
50. Okuhara T. A clinical study of garlic extract on peripheral circulation. Jpn Pharmacol Ther. 1994;22:3695-701.
51. Kim KM, Chun SB, Koo MS, Choi WJ, Kim TW, Kwon YG, Chung HT, Billiar TR, Kim YM. Differential regulation of NO availability from macrophages and endothelial cells by the garlic component S-allyl cysteine. Free Radic Biol Med. 2001;30:747-56.
52. Steiner M, Lin RS. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. J Cardiovasc Pharmacol. 1998;31:904-8.
53. Efendy JL, Simmons DL, Campbell GR, Campbell JH. The effect of the aged garlic extract, "Kyolic," on the development of experimental atherosclerosis. Atherosclerosis. 1997;132:37-42.
54. Budoff MJ, Takasu J, Flores FR, Niihara Y, Lu B, Lau BH, Rosen RT, Amagase H. Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study. Prev Med. 2004;39:985-91.
55. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-5.
56. Farkas K, Kolossvary E, Jarai Z, Nemcsik J, Farsang C. Non-invasive assessment of microvascular endothelial function by laser Doppler flowmetry in patients with essential hypertension. Atherosclerosis. 2004;173:97-102.
57. Triggle CR, Ding H, Anderson TJ, Pannirselvam M. The endothelium in health and disease: a discussion of the contribution of non-nitric oxide endothelium-derived vasoactive mediators to vascular homeostasis in normal vessels and in type II diabetes. Mol Cell Biochem. 2004;263:21-7.
58. De Vriese AS, Blom HJ, Heil SG, Mortier S, Kluijtmans LA, Van de Voorde J, Lameire NH. Endothelium-derived hyperpolarizing factor-mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia. Circulation. 2004;109:2331-6.
59. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-51.
60. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 1989;80:458-65.
61. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991;83:391-401.
62. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO 3rd0. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest. 1995;95:1747-55.
63. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-7.
64. McLenachan JM, Williams JK, Fish RD, Ganz P, Selwyn AP. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation. 1991;84:1273-8.
65. Nishimura RA, Lerman A, Chesebro JH, Ilstrup DM, Hodge DO, Higano ST, Holmes DR Jr, Tajik AJ. Epicardial vasomotor responses to acetylcholine are not predicted by coronary atherosclerosis as assessed by intracoronary ultrasound. J Am Coll Cardiol. 1995;26:41-9.
66. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long- term outcome of coronary heart disease. Circulation. 2000;101:1899-906.
67. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-54.
68. Arora S, Smakowski P, Frykberg RG, Simeone LR, Freeman R, LoGerfo FW, Veves A. Differences in foot and forearm skin microcirculation in diabetic patients with and without neuropathy. Diabetes Care. 1998;21:1339-44.
69. Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS, DeGirolami U, LoGerfo FW, Freeman R. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes. 1998;47:457-63.